
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2758815/publications.pdf Version: 2024-02-01



ASAHIDO MODISHITA

#	Article	IF	CITATIONS
1	Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. International Journal of Molecular Sciences, 2021, 22, 5801.	1.8	182
2	mi <scp>RNA</scp> in hepatocellular carcinoma. Hepatology Research, 2015, 45, 128-141.	1.8	96
3	Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. International Journal of Oncology, 2014, 45, 322-332.	1.4	80
4	Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma—A Review. International Journal of Molecular Sciences, 2020, 21, 8362.	1.8	80
5	MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. Cancers, 2021, 13, 514.	1.7	63
6	Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo. International Journal of Oncology, 2015, 46, 2419-2430.	1.4	61
7	Diabetes mellitus and metformin in hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 6100.	1.4	61
8	Cancer Therapy Due to Apoptosis: Galectin-9. International Journal of Molecular Sciences, 2017, 18, 74.	1.8	58
9	Reduced expression of cell cycle regulator p18INK4C in human hepatocellular carcinoma. Hepatology, 2004, 40, 677-686.	3.6	52
10	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. Cancer Reports, 2022, 5, e1464.	0.6	43
11	Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo. International Journal of Oncology, 2015, 46, 2172-2180.	1.4	40
12	Albumin–bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C. Hepatology Research, 2019, 49, 731-742.	1.8	40
13	Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest. International Journal of Oncology, 2017, 51, 1674-1684.	1.4	39
14	Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest. Oncology Reports, 2017, 38, 2825-2835.	1.2	39
15	Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest. Oncology Reports, 2015, 34, 1761-1770.	1.2	38
16	Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA. International Journal of Molecular Sciences, 2021, 22, 8139.	1.8	38
17	Antitumor effect of metformin on cholangiocarcinoma: In vitro and in vivo studies. Oncology Reports, 2015, 34, 2987-2996.	1.2	37
18	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Childâ€Pugh class A or B liver function in realâ€world clinical practice. Hepatology Research, 2022, 52, 773-783.	1.8	34

#	Article	IF	CITATIONS
19	The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2017, 8, 8536-8549.	0.8	33
20	Telmisartan Inhibits Cell Proliferation and Tumor Growth of Esophageal Squamous Cell Carcinoma by Inducing S-Phase Arrest In Vitro and In Vivo. International Journal of Molecular Sciences, 2019, 20, 3197.	1.8	31
21	Identification of microRNA profiles associated with refractory primary biliary cirrhosis. Molecular Medicine Reports, 2016, 14, 3350-3356.	1.1	30
22	Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study. Clinical Gastroenterology and Hepatology, 2023, 21, 370-379.	2.4	30
23	Galectin-9: An anticancer molecule for gallbladder carcinoma. International Journal of Oncology, 2016, 48, 1165-1174.	1.4	29
24	Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats. Hypertension Research, 2019, 42, 769-778.	1.5	28
25	Galectin-9 suppresses the proliferation of gastric cancer cells in vitro. Oncology Reports, 2016, 35, 851-860.	1.2	26
26	Role of microRNA-210-3p in hepatitis B virus-related hepatocellular carcinoma. American Journal of Physiology - Renal Physiology, 2020, 318, G401-G409.	1.6	26
27	Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct‑acting antiviral treatment: All Kagawa Liver Disease Group Study. Oncology Letters, 2020, 19, 2205-2212.	0.8	26
28	Effects of galectin-9 on apoptosis, cell cycle and autophagy in human esophageal adenocarcinoma cells. Oncology Reports, 2017, 38, 506-514.	1.2	25
29	The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatology International, 2020, 14, 225-238.	1.9	25
30	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLCâ€B stage patients classified as beyond up to seven criteria – Multicenter analysis. Hepatology Research, 2022, 52, 308-316.	1.8	25
31	Does firstâ€line treatment have prognostic impact for unresectable <scp>HCC</scp> ?—Atezolizumab plus bevacizumab versus lenvatinib. Cancer Medicine, 2023, 12, 325-334.	1.3	25
32	Profile of microRNAs associated with aging in rat liver. International Journal of Molecular Medicine, 2014, 34, 1065-1072.	1.8	24
33	Galectin-9 Induces Mitochondria-Mediated Apoptosis of Esophageal Cancer In Vitro and In Vivo in a Xenograft Mouse Model. International Journal of Molecular Sciences, 2019, 20, 2634.	1.8	24
34	MicroRNA profiles in various hepatocellular carcinoma cell lines. Oncology Letters, 2016, 12, 1687-1692.	0.8	23
35	Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecularâ€targeted agent sequential therapy: A propensity scoreâ€matched analysis. Hepatology Research, 2021, 51, 472-481.	1.8	23
36	A protease-activated receptor-1 antagonist protects against podocyte injury in a mouse model of nephropathy. Journal of Pharmacological Sciences, 2017, 135, 81-88.	1.1	22

#	Article	IF	CITATIONS
37	Correlation between serum galectinâ€9 levels and liver fibrosis. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 492-499.	1.4	22
38	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. Cancer Medicine, 2022, 11, 3796-3808.	1.3	21
39	Current Innovations in Endoscopic Therapy for the Management of Colorectal Cancer: From Endoscopic Submucosal Dissection to Endoscopic Full-Thickness Resection. BioMed Research International, 2014, 2014, 1-12.	0.9	20
40	Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth. International Journal of Oncology, 2015, 47, 1293-1302.	1.4	20
41	Submucosal tunneling techniques: current perspectives. Clinical and Experimental Gastroenterology, 2014, 7, 67.	1.0	18
42	Metformin-suppressed differentiation of human visceral preadipocytes: Involvement of microRNAs. International Journal of Molecular Medicine, 2016, 38, 1135-1140.	1.8	18
43	Serum microRNA‑125a‑5p as a potential biomarker of HCV‑associated hepatocellular carcinoma. Oncology Letters, 2019, 18, 882-890.	0.8	18
44	The Role of microRNAs in Cholangiocarcinoma. International Journal of Molecular Sciences, 2021, 22, 7627.	1.8	18
45	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Hepatology Research, 2022, 52, 462-470.	1.8	18
46	Aspirin inhibits hepatocellular carcinoma cell proliferation inÂvitro and inÂvivo via inducing cell cycle arrest and apoptosis. Oncology Reports, 2020, 44, 457-468.	1.2	17
47	Fibrosis Staging Using Direct Serum Biomarkers is Influenced by Hepatitis Activity Grading in Hepatitis C Virus Infection. Journal of Clinical Medicine, 2018, 7, 267.	1.0	16
48	Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest. Anti-Cancer Drugs, 2020, 31, 231-240.	0.7	15
49	Galectin‑9 suppresses the tumor growth of colon cancer <i>inÂvitro</i> and <i>inÂvivo</i> . Oncology Reports, 2021, 45, .	1.2	15
50	Primary hepatic neuroendocrine tumor: A case report. Molecular and Clinical Oncology, 2016, 4, 954-956.	0.4	15
51	MicroRNA Interference in Hepatic Host-Pathogen Interactions. International Journal of Molecular Sciences, 2021, 22, 3554.	1.8	14
52	Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis Journal of Clinical Oncology, 2021, 39, 4070-4070.	0.8	14
53	The Role of Long Non-Coding RNA and microRNA Networks in Hepatocellular Carcinoma and Its Tumor Microenvironment. International Journal of Molecular Sciences, 2021, 22, 10630.	1.8	14
54	Reduction effect of bacterial counts by preoperative saline lavage of the stomach in performing laparoscopic and endoscopic cooperative surgery. World Journal of Gastroenterology, 2014, 20, 15763.	1.4	14

#	Article	IF	CITATIONS
55	Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. International Journal of Molecular Sciences, 2021, 22, 13071.	1.8	14
56	Indications of endoscopic submucosal dissection for symptomatic benign gastrointestinal subepithelial or carcinoid tumors originating in the submucosa. Molecular and Clinical Oncology, 2013, 1, 1002-1008.	0.4	13
57	Metformin Inhibits Proliferation and Tumor Growth of QGP-1 Pancreatic Neuroendocrine Tumor Cells by Inducing Cell Cycle Arrest and Apoptosis. Anticancer Research, 2020, 40, 121-132.	0.5	13
58	Albumin–Bilirubin Score Differentiates Liver Fibrosis Stage and Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Virus Infection: A Retrospective Cohort Study. American Journal of Tropical Medicine and Hygiene, 2019, 101, 220-225.	0.6	13
59	Galectin-9 ameliorates fulminant liver injury. Molecular Medicine Reports, 2017, 16, 36-42.	1.1	12
60	Antihypertensive drug telmisartan suppresses the proliferation of gastric cancer cells inÂvitro and inÂvivo. Oncology Reports, 2020, 44, 339-348.	1.2	12
61	Analysis of the amount of tissue sample necessary for mitotic count and Ki-67 index in gastrointestinal stromal tumor sampling. Oncology Reports, 2015, 33, 215-222.	1.2	11
62	Induction of apoptosis by Galectin-9 in liver metastatic cancer cells: In vitro study. International Journal of Oncology, 2017, 51, 607-614.	1.4	11
63	MicroRNAs as possible biomarkers for hepatocellular carcinoma. Hepatology Research, 2018, 48, 499-501.	1.8	11
64	Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis. Journal of Clinical Medicine, 2019, 8, 1258.	1.0	11
65	Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma. Oncology Letters, 2020, 20, 1727-1733.	0.8	10
66	Low prevalence of biliary tract cancer with defective mismatch repair genes in a Japanese hospital‑based population. Oncology Letters, 2021, 23, 4.	0.8	10
67	Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis Journal of Clinical Oncology, 2022, 40, 416-416.	0.8	10
68	Evaluation of gastric submucosal tumors using endoscopically visualized features with submucosal endoscopy. Oncology Letters, 2014, 8, 161-168.	0.8	9
69	MicroRNA profiles during galectin‑9‑induced apoptosis of pancreatic cancer cells. Oncology Letters, 2017, 15, 407-414.	0.8	9
70	Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients. International Journal of Molecular Sciences, 2018, 19, 1940.	1.8	9
71	The Effect of Gemcitabine on Cell Cycle Arrest and microRNA Signatures in Pancreatic Cancer Cells. In Vivo, 2020, 34, 3195-3203.	0.6	9
72	Aspirin inhibits cholangiocarcinoma cell proliferation via cell cycle arrest inÂvitro and inÂvivo. International Journal of Oncology, 2020, 58, 199-210.	1.4	9

#	Article	IF	CITATIONS
73	Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?. International Journal of Molecular Sciences, 2020, 21, 4939.	1.8	8
74	Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma. International Journal of Oncology, 2017, 50, 2145-2153.	1.4	7
75	Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis. Hepatology Research, 2021, 51, 1219-1228.	1.8	7
76	Time ourse changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. Hepatology Research, 2022, 52, 235-246.	1.8	7
77	Targeted sequencing of cancer‑associated genes in hepatocellular carcinoma using next‑generation sequencing. Oncology Letters, 2018, 15, 528-532.	0.8	6
78	Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48Âweeks after off-treatment follow-up: the limitation of pre-treatment HBsAg load for the seroclearance of HBsAg. Internal and Emergency Medicine, 2021, 16, 1559-1565.	1.0	6
79	Antihypertensive drug telmisartan inhibits cell proliferation of gastrointestinal stromal tumor cells inÂvitro. Molecular Medicine Reports, 2020, 22, 1063-1071.	1.1	6
80	Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model. PLoS ONE, 2022, 17, e0261310.	1.1	6
81	Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three‑dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion. Molecular and Clinical Oncology, 2019, 11, 447-454.	0.4	5
82	Application of endoscopic hemostatic forceps for uterine cervical bleeding. Gastrointestinal Endoscopy, 2015, 81, 234-235.	0.5	4
83	Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV. Internal Medicine, 2018, 57, 1101-1104.	0.3	4
84	Clinical outcomes of hepatitisÂC virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study. Hepatology Research, 2020, 50, 557-564.	1.8	4
85	Albumin platelet product as a novel score for liver fibrosis stage and prognosis. Scientific Reports, 2021, 11, 5345.	1.6	4
86	L-carnitine reduces hospital admissions in patients with hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2021, 32, 288-293.	0.8	4
87	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Scientific Reports, 2022, 12, 8421.	1.6	4
88	Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a realâ€world setting: A large, multicenter study from Japan. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1420-1425.	1.4	3
89	Association between microRNA‑527 and glypican‑3 in hepatocellular carcinoma. Oncology Letters, 2021, 21, 229.	0.8	3
90	Multimodal treatment involving molecular targeted agents and onâ€'demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report. Molecular and Clinical Oncology, 2021, 15, 154.	0.4	3

#	Article	IF	CITATIONS
91	Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study. Cancers, 2021, 13, 4605.	1.7	3
92	Effect of the anti-diabetic drug metformin in hepatocellular carcinoma inÃ ⁻ Âį¼2vitro and inÃ ⁻ Âį½2vivo. International Journal of Oncology, 2013, , .	1.4	3
93	Macâ€2â€binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C. Hepatology Communications, 2022, 6, 1855-1869.	2.0	3
94	Evaluation of in vivo efficacy of radiofrequency ablation with D-sorbitol in animal liver. Molecular and Clinical Oncology, 2016, 4, 183-186.	0.4	2
95	A case report of granulocyte colony-stimulating factor-producing hepatocellular carcinoma that recurred after long-term complete response. Clinical Journal of Gastroenterology, 2021, 14, 204-211.	0.4	2
96	Prognosis of probable autoimmune hepatitis patients: a single-center study in Japan. Internal and Emergency Medicine, 2021, 16, 2155-2162.	1.0	2
97	Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines. International Journal of Molecular Sciences, 2022, 23, 1667.	1.8	2
98	Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells. Anticancer Research, 2022, 42, 1263-1275.	0.5	2
99	Endoscopic management with over-the-scope clips for intestinal bleeding of Behçet's disease. Gastrointestinal Endoscopy, 2015, 81, 1275-1276.	0.5	1
100	Successful mucosal incision-assisted biopsy for the histological diagnosis of duodenal lymphoma: A case report. Oncology Letters, 2016, 11, 531-534.	0.8	1
101	MicroRNA profile of hepatic epithelioid hemangioendothelioma: A case report. Oncology Letters, 2017, 13, 1655-1659.	0.8	1
102	Previous and current knowledge on cell cycleâ€related molecules in hepatocellular carcinoma: Potential therapeutic targets of cell cycleâ€related molecules in hepatocellular carcinoma. Hepatology Research, 2019, 49, 1094-1096.	1.8	1
103	Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by directâ€acting antiviral therapies. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1126-1135.	1.4	1
104	Diaphragmatic Hernia after Radiofrequency Ablation. Diagnostics, 2021, 11, 307.	1.3	1
105	Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers, 2021, 13, 2257.	1.7	1
106	Peg-IFNα-2a Contributed to HBs Antigen Seroclearance in a Patient with Chronic Hepatitis B Administered Nucleic Acid Analogs: A Three-year Follow-up. Internal Medicine, 2021, 60, 1835-1838.	0.3	1
107	Chronic hepatitis B which converting to HBs antigen negativity and HBs antibody positivity during Peg-IFNα-2a treatment after surgery for hepatocellular carcinoma: a case report. Acta Hepatologica Japonica, 2016, 57, 666-673.	0.0	0
108	Endoscopic submucosal dissection under Dâ€sorbitol solution in an animal model. Digestive Endoscopy, 2019, 31, e26-e27.	1.3	0

ASAHIRO MORISHITA

#	Article	IF	CITATIONS
109	Unusual pedunculated gastric polypoid lesion. Frontline Gastroenterology, 2021, 12, 698-699.	0.9	Ο
110	Can microRNAâ€96â€5p serve as a therapeutic molecule in the near future?. Hepatology Research, 2022, 52, 3-4.	1.8	0
111	Clinical features of hepatic dysfunction caused by immune checkpoint inhibitors and treatment of refractory cases. Acta Hepatologica Japonica, 2022, 63, 107-119.	0.0	Ο
112	MicroRNA as a Biomarker in Gastroenterological Cancers. International Journal of Molecular Sciences, 2022, 23, 4701.	1.8	0
113	Giant cutaneous metastasis from hepatocellular carcinoma. JGH Open, 0, , .	0.7	0
114	A Case of IgG4 Related Sclerosing Cholangitis with Fever Diagnosed by Hypocomplementemia. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 989-995.	0.0	0